Quick Answer
Boundless Bio, Inc. reported Operating Income of -$63.55 million for fiscal year 2025.
Boundless Bio, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$63.55M | +13.3% |
| 2024 | -$73.27M | -33.7% |
| 2023 | -$54.80M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.15M | +19.1% | +11.2% |
| June 30, 2025 | -$17.06M | +12.0% | +1.6% |
| March 31, 2025 | -$17.34M | -2.7% | +7.3% |
| September 30, 2024 | -$18.71M | -25.2% | +3.5% |
| June 30, 2024 | -$19.39M | -38.9% | -14.9% |
| March 31, 2024 | -$16.88M | -39.7% | -12.9% |
| September 30, 2023 | -$14.95M | — | -7.1% |
| June 30, 2023 | -$13.96M | — | -15.5% |
- Boundless Bio, Inc. showed an increase of +13.3% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Boundless Bio, Inc.’s operating income has declined by 16.0% (from -$54.80 million to -$63.55 million).
- The most recent figure is from Boundless Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: